AbbVie, Boehringer Settle U.S. Patent Dispute Over Drug Humira  The Wall Street Journal

AbbVie and Boehringer Ingelheim said they have resolved their U.S. patent dispute over a biosimilar to Abbvie’s Humira, the world’s biggest-selling drug.